HTA (health technology assessment) reports help manufacturers reach new market targets
This article was originally published in Clinica
Executive Summary
While a favourable health technology assessment (HTA) is no guarantee of the subsequent commercial success of a medtech product, its very existence can only have positive effects in terms of raising the profile of a new technique or procedure. That was one of the key messages from a June 19 BVMed-hosted workshop on evidence-based medicine.
You may also be interested in...
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.
First Off The Blocks, Fresenius Launches US Tocilizumab Biosimilar
Fresenius Kabi has kicked off competition to Genentech’s Actemra in the US, launching its Tyenne biosimilar version of tocilizumab.